WASHINGTON, May 6 (Reuters) - A U.S. Food and Drug Administration panel on Thursday:
* voted 20-1, with 2 abstentions, that Questcor Pharmaceuticals Inc
submitted enough evidence on the safety of Acthar for infant spasms
(Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* voted 20-1, with 2 abstentions, that Questcor Pharmaceuticals Inc
submitted enough evidence on the safety of Acthar for infant spasms
(Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.